New therapies for castrate-resistant prostate cancer

Stephen Williams, Aaron H. Lay, Clayton S. Lau, David Y. Josephson, Timothy G. Wilson, Toni K. Choueiri, Sumanta K. Pal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

Original languageEnglish (US)
Pages (from-to)2069-2074
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number13
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Therapeutics
Castration
Cytotoxins
Expert Testimony
Immunotherapy
Androgens
Cost-Benefit Analysis
Cause of Death
Research
Neoplasms

Keywords

  • castrate resistant
  • chemotherapy
  • outcomes
  • prostate cancer
  • review

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Williams, S., Lay, A. H., Lau, C. S., Josephson, D. Y., Wilson, T. G., Choueiri, T. K., & Pal, S. K. (2011). New therapies for castrate-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 12(13), 2069-2074. https://doi.org/10.1517/14656566.2011.590133

New therapies for castrate-resistant prostate cancer. / Williams, Stephen; Lay, Aaron H.; Lau, Clayton S.; Josephson, David Y.; Wilson, Timothy G.; Choueiri, Toni K.; Pal, Sumanta K.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 13, 09.2011, p. 2069-2074.

Research output: Contribution to journalArticle

Williams, S, Lay, AH, Lau, CS, Josephson, DY, Wilson, TG, Choueiri, TK & Pal, SK 2011, 'New therapies for castrate-resistant prostate cancer', Expert Opinion on Pharmacotherapy, vol. 12, no. 13, pp. 2069-2074. https://doi.org/10.1517/14656566.2011.590133
Williams S, Lay AH, Lau CS, Josephson DY, Wilson TG, Choueiri TK et al. New therapies for castrate-resistant prostate cancer. Expert Opinion on Pharmacotherapy. 2011 Sep;12(13):2069-2074. https://doi.org/10.1517/14656566.2011.590133
Williams, Stephen ; Lay, Aaron H. ; Lau, Clayton S. ; Josephson, David Y. ; Wilson, Timothy G. ; Choueiri, Toni K. ; Pal, Sumanta K. / New therapies for castrate-resistant prostate cancer. In: Expert Opinion on Pharmacotherapy. 2011 ; Vol. 12, No. 13. pp. 2069-2074.
@article{756ddf0a97754994927ab41fec67a461,
title = "New therapies for castrate-resistant prostate cancer",
abstract = "Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.",
keywords = "castrate resistant, chemotherapy, outcomes, prostate cancer, review",
author = "Stephen Williams and Lay, {Aaron H.} and Lau, {Clayton S.} and Josephson, {David Y.} and Wilson, {Timothy G.} and Choueiri, {Toni K.} and Pal, {Sumanta K.}",
year = "2011",
month = "9",
doi = "10.1517/14656566.2011.590133",
language = "English (US)",
volume = "12",
pages = "2069--2074",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "13",

}

TY - JOUR

T1 - New therapies for castrate-resistant prostate cancer

AU - Williams, Stephen

AU - Lay, Aaron H.

AU - Lau, Clayton S.

AU - Josephson, David Y.

AU - Wilson, Timothy G.

AU - Choueiri, Toni K.

AU - Pal, Sumanta K.

PY - 2011/9

Y1 - 2011/9

N2 - Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

AB - Prostate cancer is the second leading cause of cancer death in men in the USA, and most of these deaths will occur as a result of castrate-resistant prostate cancer (CRPC) that has progressed despite androgen deprivation therapy. There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies. Areas covered: This review focuses on emerging and new therapies for castrate-resistant prostate cancer, including hormonal therapy, immunotherapy and cytotoxic agents. Expert opinion: New treatment strategies have been developed in recent years and, with improved understanding of advanced CRPC, additional targeted treatments are expected in the near future. Further cost effectiveness research of these treatments is warranted before dissemination of these promising agents.

KW - castrate resistant

KW - chemotherapy

KW - outcomes

KW - prostate cancer

KW - review

UR - http://www.scopus.com/inward/record.url?scp=80051537020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051537020&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.590133

DO - 10.1517/14656566.2011.590133

M3 - Article

VL - 12

SP - 2069

EP - 2074

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 13

ER -